Laith F. Al-Rabadi
( out of 16 reviews )

Laith F. Al-Rabadi, MD

Languages spoken: English

Dr. Al-Rabadi finished his undergraduate and medical training at Jordan University of Science and Technology in 2007. Afterwards, he joined Edelman lab at Harvard-MIT Division of Health Sciences and Technology to study endothelial dysfunction in uremic milieu. Dr. Al-Rabdi finished his Internal Medicine training at University of Iowa in 2013 then moved on to begin nephrology training at Boston University-Boston Medical Center. He had the privilege to work with Dr. David Salant and developed special interest in Glomerular diseases. Dr. Al-Rabadi was also actively involved in teaching students and residents.

His clinical interests include different aspects of nephrology particularly glomerular diseases, transplant, and peritoneal dialysis. He is involved in several clinical research projects and literature reviews.

He established a unique collaboration with Dr. Laurence Beck at Boston Medical Center to initiate innovative projects related to membranous nephropathy (MN) pathogenesis with the goal of developing clinical and translational research and enhancing University of Utah role as a destination site for MN. Dr. Beck is a world-renowned expert and an authority in MN and published extensively on the pathogenesis and biomarkers in MN. He also established a collaboration with Dr. Bernstein and from Moran Eye Center to perform clinical studies related to Alport syndrome (AS). He has been working closely with Dr. Gregory who, along with Dr. Atkins, has collected samples, clinical information and pedigrees of 130 families with X- linked AS. They also identified over 30 families with probable autosomal recessive AS based on patterns of inheritance. He evaluates many patients with AS at the kidney and the transplant clinic.

He is motivated and committed to advance the field of glomerular diseases and Alport syndrome at the university of Utah

Specialties

Board Certification

American Board of Internal Medicine
American Board of Internal Medicine (Sub: Nephrology)

Patient Rating

4.7 /5
( out of 16 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

2025-12-08
UNIVERSITY HOSPITAL

Dr. Al-Rabadi was personable, explained everything well, answered my questions, and included me in the decisions.

2025-11-16
UNIVERSITY HOSPITAL

Great Doctor to help me with my illness.

2025-07-06
UNIVERSITY HOSPITAL

I like him very much so much energy on track my information was positive

2025-03-17
UNIVERSITY HOSPITAL

He was nice and knowledgeable

2025-03-17
UNIVERSITY HOSPITAL

Dr. Al-Rabadi thoroughly responded to questions and concerns I and my wife asked about my condition and adjusted my medications and testing protocol as a result. He emphasized working with other specialists at the hospital to control other systemic problems caused by my vasculitis. I was grateful when he emphasized it was important to pay attention to my symptoms, that they would be first indication of recurrence.

2024-11-25
UH HOSPITALS AND CLINICS

Great doctor

2024-01-18
UH HOSPITALS AND CLINICS

have only the best to say about Faith Al-Rabadi he has been so helpful since my sickness reared its ugly head.

2023-06-29
UH HOSPITALS AND CLINICS

Me parece excelente mdico, muy cordial, atento, escucha al paciente, explica muy bien, se ve que se preocupa por el paciente.

2023-06-01
UH HOSPITALS AND CLINICS

He is always personable, encouraging and optimistic. He provides clear concise information to explain my condition and current status. Unfortunately, like many excellent physicians, there are other demands for his time, and I will likely be seeing a different physician next time.

Dr. Al-Rabadi finished his undergraduate and medical training at Jordan University of Science and Technology in 2007. Afterwards, he joined Edelman lab at Harvard-MIT Division of Health Sciences and Technology to study endothelial dysfunction in uremic milieu. Dr. Al-Rabdi finished his Internal Medicine training at University of Iowa in 2013 then moved on to begin nephrology training at Boston University-Boston Medical Center. He had the privilege to work with Dr. David Salant and developed special interest in Glomerular diseases. Dr. Al-Rabadi was also actively involved in teaching students and residents.

His clinical interests include different aspects of nephrology particularly glomerular diseases, transplant, and peritoneal dialysis. He is involved in several clinical research projects and literature reviews.

He established a unique collaboration with Dr. Laurence Beck at Boston Medical Center to initiate innovative projects related to membranous nephropathy (MN) pathogenesis with the goal of developing clinical and translational research and enhancing University of Utah role as a destination site for MN. Dr. Beck is a world-renowned expert and an authority in MN and published extensively on the pathogenesis and biomarkers in MN. He also established a collaboration with Dr. Bernstein and from Moran Eye Center to perform clinical studies related to Alport syndrome (AS). He has been working closely with Dr. Gregory who, along with Dr. Atkins, has collected samples, clinical information and pedigrees of 130 families with X- linked AS. They also identified over 30 families with probable autosomal recessive AS based on patterns of inheritance. He evaluates many patients with AS at the kidney and the transplant clinic.

He is motivated and committed to advance the field of glomerular diseases and Alport syndrome at the university of Utah

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor (Clinical)
Pathology -Adjunct Associate Professor
Academic Divisions Nephrology & Hypertension
Board Certification
American Board of Internal Medicine
American Board of Internal Medicine (Sub: Nephrology)

Education history

Professional Medical Medicine - Jordan University of Science and Technology M.B.B.S.
Internship General Medicine - Ministry of Health Transitional Internship
Internship General Surgery - King Abdullah University Hospital Intern
Internship Internal Medicine - University of Iowa Hospitals and Clinics Intern
Residency Internal Medicine - University of Iowa Hospitals and Clinics Resident
Fellowship Nephrology - Boston Medical Center, Boston University Fellow

Selected Publications

Journal Article

  1. Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC (2016). The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol, 27(1), 189-201.
  2. Chitalia VC, Murikipudi S, Indolfi L, Rabadi L, Valdez R, Franses JW, Edelman E (2011). Matrix-embedded endothelial cells are protected from the uremic milieu. Nephrology, dialysis, transplantation, 26(12), 3858-65.
  3. Al-Rabadi L, Box T, Singhania G, Al-Marji C, Agarwal A, Hall I, Gordon CE, Tran (2018). Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. Hemodialysis international. International Symposium on Home Hemodialysis, 22 Suppl 1, S45-S52.
  4. Al-Rabadi L, Francis JM, Henderson J, Ghai (2015). Proliferative glomerulonephritis with monoclonal immunoglobulin in renal allografts. Clinical kidney journal, 8(6), 722-8.
  5. Tiffany N. Caza1¿, Laith F. Al-Rabadi2¿ and Laurence H. Beck J (2021). How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy . Frontiers in immunology,
  6. Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri Z (2021). Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. The oncologist, 26(2), 101-106.
  7. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zi'tkiewicz B (2021). Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. European journal of human genetics, 29(8), 1186-1197.
  8. Khalighi MA, Al-Rabadi L, Chalasani M, Smith M, Kakani S, Revelo MP, Meehan S (2018). Staphylococcal Infection-Related Glomerulonephritis With Cryoglobulinemic Features. Kidney international reports, 3(5), 1128-1134.
  9. Al-Rabadi LF, Beck LH J (2023). Neuronal Proteins as Antigenic Targets in Membranous Nephropathy. Nephron, 147(8), 451-457.
  10. Al-Rabadi LF, Caza T, Trivin-Avillach C, Rodan AR, Andeen N, Hayashi N, Williams B, Revelo MP, Clayton F, Abraham J, Lin E, Liou W, Zou CJ, Ramkumar N, Cummins T, Wilkey DW, Kawalit I, Herzog C, Storey A, Edmondson R, Sjoberg R, Yang T, Chien J, Merchant M, Arthur J, Klein J, Larsen C, Beck LH J (2021). Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. Journal of the American Society of Nephrology, 32(7), 1666-1681.

Review

  1. Caza T, Wijewardena C, Al-Rabadi L, Perl (2022). Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis. Translational research,

Book Chapter

  1. Al-Rabadi (2019). Renal and Metabolic Disorders Related to Alcohol and Other Drug Use.

Case Report

  1. Al-Rabadi L, Ayalon R, Bonegio RG, Ballard JE, Fujii AM, Henderson JM, Salant DJ, Beck LH Jr (2016). Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report. Am J Kidney Dis, 67(5), 775-8.
  2. Aburizik A, Singh S, Al-Rabadi L, Blosser (2014). Mistaken identity: normotensive scleroderma renal crisis.LID - 10.1136/bcr-2013-202566 [doi]LID - bcr2013202566 [pii]. BMJ case reports, 2014,
  3. Bansal S, Singhania N, Nukala CM, Singh AK, Al-Rabadi (2021). Histoplasma stomatitis unveiled: Not all opportunistic infections get better after initiation of antiretroviral therapy. Clinical case reports, 9(3), 1466-1468.
  4. Singhania N, Singhania G, Al-Rabadi (2020). Acquired Reactive Perforating Collagenosis. Clinical and experimental nephrology, 24(11), 1086-1087.
  5. Singhania N, Al-Odat R, Singh AK, Al-Rabadi (2020). Intestinal necrosis after co-administration of sodium polystyrene sulfonate and activated charcoal. Clinical case reports, 8(4), 722-724.
  6. Al-Rabadi L, Quillen K, Shashar M, Al Marji C, Jaberi A, Chitalia V, Henderson J, Salant D, Beck LH J (2017). Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. Kidney international reports, 3(2), 476-481.

Editorial

  1. Caza TN, Al-Rabadi L (2022). What Can Mercury Teach Us About Membranous Nephropathy and Minimal Change Disease?. Kidney international reports, 7(6), 1157-1160.

Abstract

  1. Al-Odat R, Al-Rabadi L, Blosser C, Francis (2014). Hypermagnesemia-induced hypothermia in a pregnant patient.
  2. Al-Rabadi LF, Al-odat RT, Blosser C (2012). Tacrolimus-Induced Thrombotic Microangiopathy Post Allogeneic Stem Cell Transplant. 23(Abstract Issue), PUB36, 902A.
  3. Erinle AO, Al-Rabadi LF, Sarker A, Gamilla-Crudo AK, Ishihara K, Beach (2008). Seronegative Anti-GBM Disease; Clinical Dilemma in Management. 19(Abstract Issue), 989A-990A.

Other

  1. Savige J, Lipska-Zietkiewicz BS, Watson E, Hertz JM, Deltas C, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Renieri A, Storey H, Flinter (2022). Guidelines for Genetic Testing and Management of Alport Syndrome. Clinical journal of the American Society of Nephrology, 17(1), 143-154.
  2. May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, Braga JR, Hassen SI, Wilson J, VanBeek C, Vankalakunti M, Barnum L, Walker PD, Bourne TD, Messias NC, Ambruzs JM, Boils CL, Sharma SS, Cossey LN, Baxi PV, Palmer M, Zuckerman JE, Walavalkar V, Urisman A, Gallan AJ, Al-Rabadi LF, Rodby R, Luyckx V, Espino G, Santhana-Krishnan S, Alper B, Lam SG, Hannoudi GN, Matthew D, Belz M, Singer G, Kunaparaju S, Price D, Chawla S, Rondla C, Abdalla MA, Britton ML, Paul S, Ranjit U, Bichu P, Williamson SR, Sharma Y, Gaspert A, Grosse P, Meyer I, Vasudev B, El Kassem M, Velez JCQ, Caza T (2021). A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney international, 100(6), 1303-1315.
  3. Huang Z, Liu S, Tang A, Al-Rabadi L, Henkemeyer M, Mimche PN, Huang (2021). Key role for EphB2 receptor in kidney fibrosis. Clinical science (London, England, 135(17), 2127-2142.
  4. Lazaro-Guevara J, Fierro-Morales J, Wright AH, Gunville R, Simeone C, Frodsham SG, Pezzolesi MH, Zaffino CA, Al-Rabadi L, Ramkumar N, Pezzolesi M (2021). Targeted Next-Generation Sequencing Identifies Pathogenic Variants in Diabetic Kidney Disease. American journal of nephrology, 52(3), 239-249.
  5. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M, Martic TN, Gupta A, van Eerde A, Gear S, Landini S, Palazzo V, Al-Rabadi L, Claes K, Corveleyn A, Van Hoof E, van Geel M, Williams M, Ashton E, Belge H, Ars E, Bierzynska A, Gangemi C, Lipska-Zi'tkiewicz B (2023). Correction: Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. European journal of human genetics,

News & Podcasts

News